Pharmaceuticals company Morepen Laboratories announced Q3FY26 results Revenue: Rs 48,416.1 lakh against Rs 45,278.01 lakh during Q3FY25, change 7%. PBT: Rs 3,542.12 lakh against Rs 3,520.59 lakh during Q3FY25, change 1%. PAT: Rs 2,749.55 lakh against Rs 2,668.85 lakh during Q3FY25, change 3%. EPS: Rs 0.5 for Q3FY26. Result PDF
Pharmaceuticals company Morepen Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue: Rs 470 crore compared to Rs 427 crore during Q4FY24, change 10%. EBITDA: Rs 47 crore compared to Rs 53 crore during Q4FY24, change -11%. EBITDA margin: 10.0% for Q4FY25. PAT: Rs 20 crore compared to Rs 29 crore during Q4FY24, change -29% PAT margin: 4.32% for Q4FY25. FY25 Financial Highlights: Revenue: Rs 1,830 crore compared to Rs 1,704 crore during FY24, change 7.4%. EBITDA: Rs 192 crore compared to Rs 173 crore during FY24, change 11.5%. EBITDA margin: 10.5% for FY25. PAT: Rs 118 crore compared to Rs 97 crore during FY24, change 22% PAT margin: 6.5% for FY25. Annual EPS up by 17% to Rs 2.20 for FY25. Result PDF